Subscribe to our feed
Subscribe by Email
- We take privacy seriously.
  Your email address will not be shared.
Pages
Search for:
Recent Comments
India Sticky Links
- Business Standard India Business Standard India – Financial Newspaper India 0
- Live Mint E Newspaper Online Version The Live Mint E Newspaper Online Version for the internet readers is a Epapercontaining indian economic and stock market news 0
- Online Fashion shop Ethnic Designs Ethnic wear and fashion tops at reasonable prices. Check out the new range of online fashion designs 0
- Times of India -Online E-newspaper The online version E-newspaper of the times of india, you can read this paper version on the internet 0
Recent Posts
Recomended Partner Blogs

Indonesia Stock Market IDX

Bollywood Movies Blog

Australian Stock Blog

Penny Stocks Australia

India shares Investment

India Curry Recipe Blog

Home Loans Guru
AL JAZEERA ENGLISH (AJE)
Indonesian stockmarket Feed
- Harga Beras Masih Fluktuatif
  Harga beras di Pasar Induk Beras Cipinang PIBC masih fluktuatif, meski cenderung naik. Harga yang sempat naik pada pekan lalu berangsur normal. […]
- Danamon Akan Tambah ATM
  PT Bank Danamon Indonesia Tbk menambah 250 mesin anjungan tunai mandiri. […]
- Electronic Arts reports huge rise in net income
  (ChinaPost.com.tw) - Electronic Arts Inc. more than doubled its fiscal first-quarter net income thanks to higher sales of video games such as “Portal 2,” “Crysis 2” and the soccer title “FIFA 11.” […]
- Samsung says 5 million Galaxy S II phones sold
  (ChinaPost.com.tw) - South Korea's Samsung Electronics, the world's second-largest mobile phone maker, said Wednesday it had sold 5 million Galaxy S II smart phones worldwide since the device debuted in April. […]

Isis Pharmaceuticals (ISIS): Profits in the Human Genome

Posted on July 29th, 2010 in biotechnology stocks, India Shares, isis, isis pharmaceuticals, john mcamant, medical technology stock letter, steven halpern, thestockadvisors.com

Filed under: Newsletters, Stocks to Buy

“Isis Pharmaceuticals (ISIS) as been a leader in genomics-based drug research since the late 1990s and has amassed an impressive intellectual property portfolio,” notes biotech specialist John McCamant.

The editor of The Medical Technology Stock Letter explains, “ISIS has successfully applied their technology to take advantage of the emergence of new genetic information. More specifically, and most important for investors, has been the ability to prolifically patent their discoveries.

“Their proprietary technologies include methods of screening drug candidates, chemical modification of the drugs to improve their efficacy, safety and biostability and methods for the manufacture of DNA and RNA-based therapeutics.

Continue reading Isis Pharmaceuticals (ISIS): Profits in the Human Genome

Isis Pharmaceuticals (ISIS): Profits in the Human Genome originally appeared on BloggingStocks on Thu, 29 Jul 2010 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

DNA – BloggingStocks – List of pharmaceutical companies – Isis Pharmaceuticals – Biotechnology